Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.BridgeBio Pharma, Inc. (BBIO) Presents at Jefferies Global Healthcare Conference 2026 Transcript
NVIDIA (NASDAQ:NVDA) Stock Sale Disclosed by Rep. Gilbert Ray Cisneros, Jr.
BridgeBio to Present New Acoramidis Data on Kidney Function, Real-World Outcomes, and First-Line Treatment Patterns in ATTR-CM at the International Symposium on Amyloidosis 2026
BridgeBio to Participate in November and December Investor Conferences
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio to Present New Acoramidis Data on Heart Failure Events in ATTR-CM at the American Heart Association Scientific Sessions 2026
Should You Invest $1,000 in BridgeBio Pharma Right Now?
BridgeBio Pharma, Inc. (BBIO) Q3 2026 Earnings Call Transcript
What BridgeBio Pharma (BBIO) Said on Its Q3 Earnings Call
BridgeBio Pharma (BBIO) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
BridgeBio Pharma (BBIO) Reports Q3 Loss, Beats Revenue Estimates
BridgeBio Pharma Q3 2026 Earnings Call Transcript
BridgeBio Reports Third Quarter 2026 Financial Results and Corporate Updates
BridgeBio to Report Third Quarter 2026 Financial Results and Commercial Updates on October 29, 2026 at 4:30 pm ET
4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Rep. Gilbert Ray Cisneros, Jr. Acquires Shares of Taiwan Semiconductor Manufacturing Company Ltd. (NYSE:TSM)
BridgeBio: Maintaining 'Strong Buy' Additional Encaleret Data ADH1 And Three Expected FDA Reviews
Acoramidis Associated with Significantly Improved Clinical Outcomes Versus Tafamidis in ATTR-CM in an Independent, Real-World Study of U.S. Electronic Health Records
FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing